Business

Enlivex Reports Positive Two-Year Clinical Outcome For A Hospitalized Patient with Erosive Osteoarthritis Treated with Allocetra

* Significant short and long-term clinical improvement for a hospitalized patient with a rare disease that currently has no effective treatment options * Nes

articleEnlivex Ltd.November 18, 20203/company/enlivex-therapeutics-ltd/news/enlivex-reports-positive-two-year-clinical-outcome-for-a-hospitalized-patient-with-erosive-osteoarthritis-treated-with-allocetra
Enlivex Reports Positive Two-Year Clinical Outcome For A Hospitalized Patient with Erosive Osteoarthritis Treated with Allocetra

About this update from Enlivex Ltd.

[{"type":"text","content":"* Significant short and long-term clinical improvement for a hospitalized patient with a rare disease that currently has no effective treatment options *\n Nes Ziona, Israel, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage immunotherapy company, today reported a positive two-year clinical outcome following the first Allocetra™ treatment of a hospitalized patient with erosive osteoarthritis, a rare bone disease, which has no approved nor effective treatment options and typically involves rapid destruction of hip and shoulder bones. This was the sole erosive osteoarthritis patient who has been treated with Allocetra™ to date. A 70-year-old patient experienced a four-year inflammatory and erosive process of the right shoulder, resulting in complete destruction of the humeral head on X-ray, significant inflammatory reaction on MRI, and significantly elevated inflammatory biomarkers in the shoulder, including erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Following regulatory approvals for compassionate use, the patient was treated with five consecutive weekly intra-shoulder joint infusions of autologous Allocetra™ (100 x 106 cells). Prior to receiving AllocetraTM, the patient had been hospitalized for more than nine months, and treatments with steroids, antibiotics and other procedures had been ineffective. Following AllocetraTM treatment, the patient improved considerably and was released from the hospital following the initial administration of AllocetraTM. A significant reduction in shoulder swelling was observed, with fluid drainage from the shoulder declining from 150–250 ml/day to","length":1901,"tagName":"div"}]

More updates from Enlivex Ltd.